Astrana Health, Inc. (NASDAQ:ASTH) Given Average Rating of "Moderate Buy" by Analysts

Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $53.29.

Several brokerages have recently weighed in on ASTH. Barclays began coverage on Astrana Health in a research report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 price target on the stock. Bank of America decreased their target price on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Truist Financial reduced their price target on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. Stifel Nicolaus dropped their price objective on Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Finally, Robert W. Baird cut their target price on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd.

Hedge Funds Weigh In On Astrana Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASTH. Stifel Financial Corp bought a new position in Astrana Health in the 3rd quarter valued at $800,000. Barclays PLC acquired a new position in Astrana Health during the 3rd quarter valued at approximately $4,457,000. Geode Capital Management LLC acquired a new stake in Astrana Health during the 3rd quarter worth about $58,995,000. Franklin Resources Inc. acquired a new position in Astrana Health in the 3rd quarter worth approximately $1,187,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Astrana Health during the third quarter worth $13,383,000. 52.77% of the stock is owned by institutional investors.

Astrana Health Stock Performance

Shares of ASTH traded down $1.01 during trading hours on Monday, hitting $30.40. The company's stock had a trading volume of 30,585 shares, compared to its average volume of 275,862. The company has a market cap of $1.52 billion, a price-to-earnings ratio of 23.27, a PEG ratio of 1.37 and a beta of 1.04. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The business has a 50 day simple moving average of $31.34 and a two-hundred day simple moving average of $38.51. Astrana Health has a 52-week low of $23.12 and a 52-week high of $63.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. On average, equities analysts expect that Astrana Health will post 1.15 earnings per share for the current fiscal year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.